	US 12,466,871 B2
	Fusion protein for use in the treatment of HVG disease
Elmar Jäckel, Hannover (DE); Fatih Noyan, Hannover (DE); and Michael Hust, Braunschweig (DE)
Assigned to Medizinische Hochschule Hannover, Hannover (DE); and Technische Universität Braunschweig, Braunschweig (DE)
Filed by Medizinische Hochschule Hannover, Hannover (DE); and Technische Universität Braunschweig, Braunschweig (DE)
Filed on Oct. 5, 2021, as Appl. No. 17/494,610.
Application 17/494,610 is a continuation of application No. 16/310,312, granted, now 11,160,831, previously published as PCT/EP2017/065472, filed on Jun. 22, 2017.
Claims priority of application No. 16177208 (EP), filed on Jun. 30, 2016.
Prior Publication US 2022/0133796 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 40/22 (2025.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/41 (2025.01); A61P 37/06 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/31 (2025.01); A61K 40/416 (2025.01); A61K 40/418 (2025.01); A61P 37/06 (2018.01); C07K 16/2833 (2013.01); C07K 19/00 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); A61K 2239/38 (2023.05); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)]

11 Claims

1. A method of treating HvG disease in a patient, comprising administering to said patient a fusion protein comprising a single-chain variable fragment antibody domain (scFv), a hinge, a transmembrane domain, an intracellular hCD28 signalling domain and an intracellular hCD3ζ (hCD3 zeta) signalling domain forming a chimeric antigen receptor having specificity for HLA-A*02 (CAR-A*02), wherein the fusion protein is expressed in a CD4+CD25+CD127low human regulatory T (Treg) cell, which Treg that express the CAR-A*02 is HLA-A*02 negative, wherein the patient is HLA-A*02 negative and contains or is intended to contain a solid tissue transplant which is HLA-A*02 positive.